These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 35774424)

  • 41. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.
    Xiong A; Wang J; Zhou C
    Front Oncol; 2021; 11():757993. PubMed ID: 34900707
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.
    Kerrigan K; Puri S
    Curr Oncol Rep; 2022 Jan; 24(1):113-123. PubMed ID: 35060001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review.
    Olivares-Hernández A; González Del Portillo E; Tamayo-Velasco Á; Figuero-Pérez L; Zhilina-Zhilina S; Fonseca-Sánchez E; Miramontes-González JP
    Ann Transl Med; 2023 Aug; 11(10):354. PubMed ID: 37675322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.
    Yeh J; Marrone KA; Forde PM
    J Thorac Dis; 2018 Feb; 10(Suppl 3):S451-S459. PubMed ID: 29593890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety.
    Shao L; Lou G
    J Thorac Dis; 2022 Sep; 14(9):3565-3574. PubMed ID: 36245597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
    Wang S; Mao Y
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tackling the immunotherapy conundrum: advances and challenges for operable non-small-cell lung cancer treatment.
    Attieh F; Chartouni A; Boutros M; Mouawad A; Kourie HR
    Immunotherapy; 2023 Nov; 15(16):1415-1428. PubMed ID: 37671552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.
    Sim JK; Choi J; Lee SY
    Korean J Intern Med; 2023 Nov; 38(6):787-796. PubMed ID: 37939663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
    Godoy LA; Chen J; Ma W; Lally J; Toomey KA; Rajappa P; Sheridan R; Mahajan S; Stollenwerk N; Phan CT; Cheng D; Knebel RJ; Li T
    Biomark Res; 2023 Jan; 11(1):7. PubMed ID: 36650586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC.
    Roller JF; Veeramachaneni NK; Zhang J
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35159008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
    Broderick SR
    Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy in non-small cell lung cancer: Update and new insights.
    Mielgo-Rubio X; Uribelarrea EA; Cortés LQ; Moyano MS
    J Clin Transl Res; 2021 Feb; 7(1):1-21. PubMed ID: 34104805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.